IMNMImmunome, Inc.
Price
+108%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth steady, the market undecided.
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Immunome, Inc. (IMNM) reported revenue of $5.0M in Q2 2026 (quarter ended Jun 30, 2026), up 25% from the same quarter a year earlier. That came with net loss of $73M. For the full year FY2025, revenue was $6.9M (−23% year on year) and net income −$212M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Amendment to License Agreement On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated …Material agreement entered · Form 8-K
- Aug 11, 2026Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 12, 2026Immunome Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.